DB18160InvestigationalGene Therapies
VO659 is an antisense oligonucleotide being investigated for the treatment of Huntington's disease.
- Also known as
- an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA)
- Code names
- VO-659
Resolves to
Compound
What you can answer from here — as of October 05, 2023
Which companies are running trials of VO659, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account